Biogen Initiates Phase-III Multiple Sclerosis Trial
To enroll more than 1,200 patients between the ages of 18 and 55
Biogen has enrolled its first patient in phase III, randomized, double-blind, placebo-controlled trial, designed to evaluate the efficacy and safety of PEGylated interferon beta-1a (BIIB017) in patients with relapsing multiple sclerosis (RMS).
The study will enroll more than 1,200 patients with RMS, between the ages of 18 and 55. The primary objective is to determine the efficacy of PEGylated interferon beta-1a in reducing the annualized relapse rate in patients with RMS at one year.
The study will also examine if, over time, treatment with PEGylated interferon beta-1a can slow disease progression and lead to a decrease in the number of T2 hyperintense brain lesions, commonly seen in MS patients.
Peter Calabresi, Principal Investigator of the ADVANCE trial, said: “Examined in Phase I studies, PEGylated interferon beta-1a was shown to be much longer acting than intramuscular interferon beta-1a and thus offers the possibility of every two or four week dosing without compromising efficacy. This could greatly increase the convenience of this first line class of therapy.
Related Insight
Suppliers Directory
EnviroChemie - Reliable Water and Wastewater Treatment
As partners to the industry, we develop and implement customised solutions by concentrating all our efforts in meeting the individual requirements of our customers.
Suppliers
Echo Pharmaceuticals - Advanced Technology Platform for Drug Delivery Systems, Formulation and Isolation
Echo Pharmaceuticals is a technology-based pharmaceutical drug development company, with a patented drug delivery technology, Alitra™, to formulate lipophilic active drug candidates into optimal delivery systems and innovative medicines suitable for clinical trials.
Drug Research > Drug Delivery > Suppliers
Bactimm - Pharmaceutical Microbiology
Bactimm & Farmalyse are contract service providers for the pharmaceutical industry, hospitals and the medical device industry, offering a full range of laboratory investigation services, quality control testing and validation services for clean rooms, processes and disinfectants.
Suppliers
BioKinetic Europe - Phase I/II Contract Research Organisation
BioKinetic Europe is an independent owner-managed Phase I/II Clinical Pharmacology Unit based in Belfast, Northern Ireland. Specialists in First in Man and Vaccine Studies, we have experience in 400+ clinical trials across all therapeutic areas using innovative trial designs.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Blister Packaging of Oral Solids – Challenges for the Pharma Industry and Patient Implications
Published by Honeywell Aclar® Films
Packaging > White Papers
Fermion Opens New Storage Facility for Large Volume APIs
Published by Fermion
White Papers
Tips & Tricks - GPC/SEC: Absolute or True Molar MAsses for MAcromolecules - Mass Spectrometry as a New Solution
Published by Polymer Standards Service
White Papers
Digital ECG
Published by CoreLab Partners
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.